title: [Application of activated eptacog alfa in cardiac surgery].
abstract: Severe bleeding in cardiac surgery is often difficult to treatment. Antybleeding drugs often are out of order. The aim of the study was to assess the efficacy of activated eptacog alfa treatment of patients with massive postoperative bleeding, which can not be controlled with conventional therapy
  
  
  METHODS
  Activated eptacog alfa was used in 18 patients after cardiac surgery. The patients had normal results of coagulation screening prior to surgery. We evaluated the average blood loss prior to and after administration of activated eptacog alfa. The average dose was 30.95 mcg/kg following administration of drugs antybleeding, transfusion KKCz, FFP, cryoprecipitate, PLT was decided to include the treatment of activated eptacog alfa.
  
  
  RESULTS
  At a dose of 30.95 mcg/kg, bleeding stopped in 12 patients. 6 patients required reoperation because of persistent bleeding.
  
  
  CONCLUSIONS
  Administration of activated eptacog alfa clearly limits the amount of transfused blood products. Activated eptacog alfa improves outcomes in patients with intractable postoperative bleeding cardiac surgery. Stops bleeding in patients who received preoperative clopidogrel. 1 patient required reoperation after administration of activated eptacog alfa.
authors.affiliation: 10 Wojskowy Szpital Kliniczny w Bydgoszczy, Klinika Kardiologii i Kardiochirurgii, Kliniczny Oddzial Kardiochirurgii. maciejzag@poczta.fm
authors.forename: Maciej
authors.initials: M
authors.lastname: Zagórski
authors.forename: Aleksander
authors.initials: A
authors.lastname: Goch
mesh_terms: D000328:Adult; D000368:Aged; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D006348:Cardiac Surgical Procedures / Q000009:adverse effects*; D000077144:Clopidogrel; D015942:Factor VIIa / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D011292:Premedication; D011994:Recombinant Proteins / Q000627:therapeutic use; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D010975:Platelet Aggregation Inhibitors; D011994:Recombinant Proteins; D000077144:Clopidogrel; C103587:recombinant FVIIa; D015942:Factor VIIa; D013988:Ticlopidine